A Multi-Level Trauma-Informed Approach to Increase HIV Pre-exposure Prophylaxis Initiation Among Black Women

Launched by JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH · Nov 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying ways to help Black women start a medication called PrEP, which can prevent HIV. The researchers have noticed that many Black women face challenges, such as intimate partner violence and discrimination, which can make it harder for them to access this important prevention method. The goal of the study is to create and test a program that addresses these challenges and encourages more Black women, especially those experiencing violence, to begin using PrEP in Baltimore.

To be eligible for the study, participants need to be Black women who are at least 18 years old, HIV-negative, and have had unprotected sex with a male partner in the past six months. They should also have specific risk factors for HIV, such as having an HIV-positive partner or not using condoms regularly. Participants will receive support and resources to help them start PrEP, and their experiences will be evaluated to see how effective the program is. This trial is currently recruiting participants, and it aims to make a real difference in improving HIV prevention for Black women.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • self-identified Black cisgender woman;
• • self-reported HIV-negative status, and
• • ≥18 years.
• • reports unprotected vaginal or anal sex in the past 6 months with a male sexual partner,
• • have at least one substantial HIV risk factor in the past 6 months according to the 2021 Centers for Disease Control (CDC) PrEP Eligibility Guidelines (i.e., HIV-positive sexual partner, recent bacterial Sexually Transmitted Disease (STD), 2+ sex partners, history of inconsistent or no condom use, commercial sex work, and residing in high HIV prevalence area or network), and
• • never taken PrEP
• Exclusion Criteria:
• • non-English speaking and
• • currently living with HIV